SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

Goldman Sachs upgrade to Buy after a sharp selloff fueled hopes of a rebound, but traders debated whether the upgrade could overcome ongoing financing concerns, especially as the rally faded. Bulls point to AI demand, customer commitments and Nvidias support, while bears remain focused on CoreWeaves heavy debt burden and borrowing costs.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

A stronger-than-expected third-quarter report and managements upbeat 2027 outlook have driven CLFs sharp rally, with bullish traders focused on improved steel pricing and possible short covering. Others question whether the outlook can overcome the companys debt and execution concerns, and some view the move as a sell-the-news bounce.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras shares are under heavy pressure amid IPO lockup-related selling concerns and a broader AI and semiconductor pullback, with traders also questioning the companys valuation, growth, and ability to scale. Bears expect further downside as more shares become eligible for sale, while bulls view the selloff as excessive and are averaging in.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

The FDAs early expansion of ANKTIVA plus BCG to papillary-only BCG-unresponsive bladder cancer, alongside long-term data showing durable responses, is driving discussion about a larger patient market and future sales. Traders are puzzled by the share-price decline despite the positive developments, debating a sell-the-news reaction and broader biotech weakness versus unverified claims of short-selling or options-related pressure.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazons advance is drawing attention after Morgan Stanley named it a top pick, citing AWS growth, AI opportunities and warehouse automation as potential catalysts. Traders are broadly bullish on the move, though some remain cautious about heavy AI spending and whether the shares can sustain gains ahead of earnings.

Sea Ltd. is an internet and mobile platform company, which engages in the provision of online gaming services. It operates through the following segments: Digital Entertainment, E-Commerce, and Digital Financial Services. The Digital Entertainment segment offers and develops mobile and PC online games. The E-Commerce segment manages a third-party marketplace through the Shopee mobile app and websites that connect buyers and sellers. The Digital Financial Services segment includes a variety of payment services and loans to individuals and businesses through SeaMoney. Sea was founded by Xiao Dong Li, Gang Ye, and Jing Ye Chen on May 8, 2009 and is headquartered in Singapore.

Sea Ltd - ADR

Sea shares are under pressure amid a sharp pullback, with traders pointing to repeated insider sales and a reported DBS downgrade as potential reasons for the weakness; some also cite broader Indonesia and Southeast Asia market concerns. Bulls argue the selling was planned and the business remains strong, while bears see insider selling and weak price action as warning signs.

X-Energy, Inc. engages in the development of advanced small modular nuclear reactors and fuel technology for clean energy generation. Its solutions include Xe-100 and TRISO-X. The company was founded by Kam Ghaffarian and Eben Mulder in 2009 and is headquartered in Rockville, MD.

X-Energy Inc. - Ordinary Shares- Class A

X-Energy Inc

Sharp post-IPO selling and volatile trading dominate the discussion, with traders pointing to lockup-related supply, bearish analyst coverage, and weakness across nuclear stocks as possible pressures. Bulls are treating the pullback as an opportunity, citing Amazons backing and X-energys potential role in meeting future data-center power demand, while others stress that reactor commercialization remains years away.

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for hematologic diseases. It assembles a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. The company was founded in October 2017 and is headquartered in Watertown, MA.

Disc Medicine Inc

Disc Medicine shares are surging after bitopertin met all primary and secondary endpoints in the Phase 3 APOLLO trial for erythropoietic protoporphyria, supporting a planned FDA resubmission. Traders are broadly reacting positively, while debating short-squeeze potential and flagging dizziness and sharp price swings as concerns.

Almonty Industries, Inc. engages in the mining, processing, and shipment of tungsten concentrates. Its projects include Almonty Korea Tungsten, Panasquiera mine, Gentung, Almonty Korea Moly, Los Santos mine, and Valtreixal. The company was founded on September 28, 2009 and is headquartered in Dillon, MT.

Almonty Industries Inc

Almontys investor-day webcast is drawing criticism, with traders disappointed by CEO Lewis Blacks presentation and questioning whether it offered meaningful new information. Some speculate that management appeared evasive, but those concerns are unverified; broader weakness in critical-minerals stocks is also part of the discussion.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is drawing attention after a sharp selloff alongside other AI neocloud stocks, as traders debate financing costs and whether the sectors growth can justify its heavy capital needs. Some see the rebound and analyst support as a buying opportunity, while others call it a short-lived bounce and expect more pressure.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SLS Stock Climbs Pre-Market: CEO's Early Anniversary Post Has Retail Bulls Buzzing About Major News

Equity

Stergiou said SELLAS was entering its “next chapter” with GPS and SLS009 but did not disclose a clinical trial timeline or confirm an upcoming announcement.


Biotech ETF (BBC) Touches a New 52-Week High

The BBC ETF hit a 52-week high as strong trial updates and biotech momentum raise hopes for more gains ahead.

Biotech ETFs Put Up Strong Show in 1H 2026: More Gains Ahead?

Biotech ETFs are surging in 2026 as a friendlier FDA, strong M&A activity and AI-driven drug discovery fuel optimism for more upside.

Biotech ETF (BBC) Touches Fresh 52-Week High

Biotech ETF BBC hits a 52-week high, likely fueled by strong clinical trial results and rising M&A activity, and renewed risk-on sentiment.

Why Did NGNE Stock Surge 25% In Pre-Market Today?

The company said that the U.S. Food and Drug Administration granted a key designation for its investigational gene therapy targeting Rett syndrome.

Why Did UPB Stock Plunge 40% Today?

The company announced positive top-line results from its Phase 2 VALIANT trial evaluating Verekitug in adults with severe asthma.

ABUS Stock On Track For Biggest Intraday Drop In Over 5 Years – What’s The Issue Around Its Patent In Europe?

The European Patent Office revoked its patent following opposition proceedings brought by affiliates of Moderna and Merck.

GLUE Stock Slips Pre-Market After Pricing $300 Million Public Offer At Discount

The offering includes 11.125 million shares of common stock priced at $24.00 per share, a 5.1% discount to Thursday’s close at $25.31.

Why Did GLUE Stock Surge Over 50% In Premarket Today?

Monte Rosa Therapeutics reported positive interim Phase 1 data for MRT-8102, showing significant anti-inflammatory effects in patients with elevated cardiovascular risk.

Can ETF Winners of Q4 of 2025 Rally in Q1 of 2026?

Q4's top ETF winners -- silver, biotech and lithium -- outpaced markets. Can SIVR, SLV, BBC and LITP extend gains into 2026?

ETFis Series Trust I - Virtus Biotech Clinical Trials ETF

Bullish Sentiment

<ul class="summary-bullets"><li>In a LinkedIn post, SELLAS Life Sciences CEO Angelos Stergiou marked the company’s 15th anniversary by reflecting on its evolution.</li><li>The CEO highlighted the company’s progress in advancing late-stage oncology programs.</li><li>The post did not provide a timeline for clinical updates, but its references to SELLAS’ “next chapter” prompted speculation among retail investors about a possible upcoming catalyst.</li></ul>SELLAS Life Sciences (SLS) shares rose in early morning trade on Monday after an anniversary post from CEO Angelos Stergiou on LinkedIn sparked speculation among retail investors that major news may be on the horizon.&nbsp;In a&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.linkedin.com/posts/dr-angelos-m-stergiou-md-scd-hc-14140b8_fifteen-years-ago-this-week-sellas-life-share-7517893213051990016--G3U/">post</a> on LinkedIn, Stergiou marked SELLAS’ 15th anniversary and said the company is stepping into its “next chapter” with its two lead programs, GPS and SLS009. The post thanked shareholders, partners, employees and trial participants. It did not mention trial timing.<a href="https://stocktwits.com/symbol/SLS">SLS stock</a> gained as much as 1.5% in pre-market trade and was among the top trending tickers on Stocktwits at the time of writing.&nbsp;<h2 class="st-heading-2">Why SELLAS Investors Are Reading Into The CEO’s Post</h2>On Stocktwits, retail sentiment around SLS stock trended in ‘bullish’ territory over the past day, accompanied by chatter at ‘high’ levels. Platform data showed a 90% increase in message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_10_19_082540_30139bbdb2.png" alt="Screenshot 2026-10-19 082540.png" width="1264" height="688"><figcaption>SLS stock retail sentiment on October 19 as of 8:00 a.m. ET | Source: Stocktwits</figcaption></figure>Some retail investors questioned whether the timing and wording of the anniversary message pointed to an upcoming catalyst.&nbsp;<stembedurl>https://stocktwits.com/sarahrah/message/666816915</stembedurl>Another investor pointed to Stergiou’s relative silence over the preceding three months and speculated that the “transition language” could signal a major corporate development.&nbsp;<stembedurl>https://stocktwits.com/Issidur/message/666816256</stembedurl>Others were less convinced. “This is nothing more than a victory lap,” one user&nbsp;<a href="https://stocktwits.com/Petey3163/message/666817123">wrote</a>. Another bullish investor also&nbsp;<a href="https://stocktwits.com/BioTechBling/message/666816222">viewed</a> the post as a victory lap but said they expected trial news to follow.<h2 class="st-heading-2">REGAL Trial Remains The Main Catalyst</h2>Investors are primarily watching the final analysis of GPS (galinpepimut-S), an immunotherapy that targets the WT1 protein found in many tumor types. SELLAS licenses the treatment from Memorial Sloan Kettering Cancer Center and is evaluating it in the Phase 3 REGAL trial in patients with acute myeloid leukemia (AML) who achieved complete remission after second-line salvage therapy. The trial’s primary endpoint is overall survival.REGAL passed its interim futility, efficacy and safety review at 60 deaths in early 2025. The final analysis is triggered at 80 deaths. SELLAS reported 72 deaths as of December 26 last year and 78 as of May 11, 2026.A German report in August claimed the threshold had been reached, but SELLAS has not confirmed that report. Investors are&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sls-stock-retail-bulls-ash-embargo-keeping-regal-results-under-wraps/cZx8BVNRBtC">now watching</a> for announcements at the American Society of Hematology's (ASH) annual meeting in New Orleans for clues on Sellas’ next clinical update.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/elon-musk-roadster-nvidia-space-ai-push-nadella-security-warning-mag-7-ceos-this-week/cZxjushRBtE">Elon Musk’s Roadster, Nvidia’s Space AI Push, Nadella’s Security Warning: Mag 7 Voices This Week</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the SELLAS Life Sciences Group logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Stergiou said SELLAS was entering its “next chapter” with GPS and SLS009 but did not disclose a clinical trial timeline or confirm an upcoming announcement.

SLS Stock Gains Pre-Market: CEO’s ‘Next Chapter’ Message Has Retail Traders Looking For A Catalyst

ETFis Series Trust I - Virtus LifeSci Biotech Clinical Trials ETF

SELLAS Life Sciences Group Inc

SPDR S&P Biotech ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$40.12
Prev Close	$39.12
Open	$39.85
Dividend Yield	N/A
50-Day Moving Average	$49.25
Beta	N/A
Avg. Volume	17,898.39
PE Ratio	N/A

52-Week High	$56.18
52-Week Low	$28.73
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

Feed

News

Sentiment

Fundamentals

Info

BBC Fundamentals